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CASE PRESENTATION
Positive 14-3-3 and tau proteins in a sporadic Creutzfeldt-Jakob 
disease case and a brief perspective of prion diseases in Colombia
Kevin Escandón-Vargas, Andrés Zorrilla-Vaca, Raúl Helí Corral-Prado
Escuela de Medicina, Facultad de Salud, Universidad del Valle, Cali, Colombia
Prion diseases are rare neurodegenerative disorders occurring worldwide and affecting both humans 
and animals. Herein, we present the case of a patient diagnosed with definite sporadic Creutzfeldt-
Jakob disease in Cali, Colombia. Besides neurological examination, 14-3-3 and tau proteins were 
valuable tools supporting the diagnosis. We also present a brief perspective of the prion diseases 
reported in Colombia to date. Although the incidence of prion diseases is unknown in Colombia, 
our literature review revealed that one case of scrapie in 1981 and 29 human sporadic cases of 
Creutzfeldt-Jakob disease have been documented and published in our country.
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Proteínas 14-3-3 y tau positivas en un caso de enfermedad esporádica de Creutzfeldt-Jakob y 
una breve reseña de las enfermedades priónicas en Colombia
Las enfermedades priónicas son alteraciones neurodegenerativas raras que ocurren en todo el 
mundo y afectan tanto a humanos como a animales. En el presente artículo, se reporta un caso 
con diagnóstico confirmado de enfermedad esporádica de Creutzfeldt-Jakob. Además del examen 
neuropatológico, las proteínas 14-3-3 y tau fueron herramientas valiosas que ayudaron en el 
diagnóstico. También, se presenta una breve reseña de las enfermedades priónicas reportadas 
en Colombia hasta la fecha. Aunque en el país se desconoce la incidencia de las enfermedades 
priónicas, nuestra búsqueda en la literatura científica reveló informes publicados sobre un caso 
de tembladera de las ovejas (scrapie o encefalopatía espongiforme ovina) en 1981 y 29 casos 
esporádicos de Creutzfeldt-Jakob en el país.
Palabras clave: síndrome de Creutzfeldt-Jakob, priones, informes de casos. 
doi: http://dx.doi.org/10.7705/biomedica.v36i3.2729
Prion diseases, also known as transmissible 
spongiform encephalopathies, are a family of 
rare, invariably fatal neurodegenerative disorders 
which occur worldwide and affect both humans 
and animals. Human transmissible spongiform 
encephalopathies currently include sporadic, 
familial, iatrogenic and variant Creutzfeldt-Jakob 
disease (s, f, i, and vCJD, respectively), and 
other syndromes such as Gerstmann-Sträussler-
Scheinker syndrome, kuru, fatal familial insomnia, 
sporadic fatal insomnia and the recently discovered 
prion protein cerebral amyloid angiopathy and 
variably protease-sensitive prionopathy. Most of 
the transmissible spongiform encephalopathies 
are sporadic, whereas only a minority are hereditary 
or acquired (1-3).
The recognition of human prion diseases is a 
medical challenge due to the small number of 
cases; sCJD accounts for around 85% of cases 
of Creutzfeldt-Jakob disease and has a global 
incidence of about one case per million people per 
year (1,4). Herein, we present the case of a patient 
diagnosed with definite sCJD in Cali, Colombia. 
Besides neurological examination, 14-3-3 and 
tau proteins were tools supporting the diagnosis. 
30
Biomédica 2016;36(Supl.1):29-36Escandón-Vargas K, Zorrilla-Vaca A, Corral-Prado RH
Additionally, we conducted a literature search 
on PubMed/Medline, Google Scholar, Bireme/
Lilacs and SciELO databases from inception 
through 2015 using the English/Spanish terms for 
“Creutzfeldt-Jakob syndrome”, “prion diseases” 
and “prions”, to present a brief perspective of the 
prion diseases reported in Colombia.
Case report
In 2011, a 53-year-old Afro-Colombian man from 
Florida, Valle del Cauca, in southwestern Colombia, 
presented to a referral medical center in Cali with 
two months of dizziness, behavior changes, speech 
impairment, gait imbalance and disorientation. The 
patient worked as a cane cutter and had never 
traveled abroad. He was hypertensive and a smoker, 
and there was no personal or familial history of 
neurodegenerative diseases or neurosurgery.
On admission, he had cognitive impairment, vision 
loss, aphasia, and ataxia. There were no signs of 
meningeal irritation. Metabolic, toxic, neoplastic and 
rheumatologic causes were screened but routine 
laboratory analyses were reported as normal. HIV, 
syphilis, HTLV, cytomegalovirus, Epstein-Barr virus, 
hepatitis B virus, and hepatitis C virus were ruled 
out. Initial brain magnetic resonance imaging (MRI) 
scan was normal. His functional and neurological 
status began declining and he entered a state 
of rapidly progressive dementia accompanied 
by generalized myoclonus and occasional tonic-
clonic seizures. Soon after, the patient developed 
akinetic mutism and prostration. Cerebrospinal 
fluid (CSF) obtained in three lumbar punctures did 
not show abnormalities. During hospitalization the 
patient had several healthcare-associated infections 
including catheter-related Staphylococcus aureus 
bacteremia, pneumonia, urinary tract infection and 
an infected sacral pressure ulcer, all of which were 
treated appropriately.
Four weeks after hospital admission, the patient 
underwent electroencephalogram (EEG) which 
revealed abundant periodic, triphasic sharp-wave 
complexes superimposed on a slow cerebral 
electrical rhythm (figure 1). During the second 
month of hospitalization, two new brain MRI studies 
showed progressive, symmetric, cortical-subcortical 
atrophy, and hyperintensive signals in the caudate 
nucleus, putamen, thalami, periaqueductal gray 
matter, right cerebellum, and parts of parietal and 
temporal cortices on T2-weighted (T2W), diffusion-
weighted imaging (DWI), and fluid-attenuated 
inversion recovery (FLAIR) sequences. Proton mag-
netic resonance spectroscopy revealed reduced 
N-acetylaspartate to creatine (NAA:Cr) ratios and 
increased choline to creatine (Cho:Cr) ratios in the 
global cerebral parenchyma (figure 2).
A 14-3-3 protein test performed in CSF by 
immunoblot was positive. Also, an ELISA immuno-
assay for the tau protein was reported as positive 
(21,789 pg/ml; decision point: 1,150 pg/ml). The 
patient died five months after disease onset. 
Autopsy was conducted for neuropathological 
examination which demonstrated the presence 
of spongiform changes, neuronal loss and gliosis. 
A definite sCJD diagnosis was made according to 
MRI-CJD Consortium (MCC) criteria (5).
Discussion
Sporadic CJD is the most frequent prion disease 
in humans and is secondary either to spontaneous 
conversion of the normal cellular prion protein 
(PrPC) into a disease-causing protease-resistant 
prion protein (PrPSc) or to somatic mutation of the 
PrP-encoding gene PRNP (1,2,4).
Physicians should consider sCJD as a differential 
diagnosis in patients with rapidly progressive 
dementia and be familiar with the available diag-
nosis tools according to the accepted criteria. sCJD 
can be diagnosed based on: (a) the World Health 
Organization (WHO) consultation group criteria 
published in 1998 (6); (b) the University of California 
San Francisco (UCSF) group criteria published in 
2007 (only for probable sCJD diagnosis) (7), or 
(c) the MCC criteria published in 2009 (5). These 
diagnostic criteria are outlined in table 1. As noted, 
definite diagnosis of sCJD requires pathological 
studies of the brain. Probable diagnosis of sCJD 
requires neurological manifestations and at least 
one positive test. Among diagnostic tests, while 
WHO and MCC criteria include 14-3-3 protein 
Figure 1. Electroencephalogram performed showing several 
periodic, triphasic sharp-wave complexes alternating with a 
slow background rhythm
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test, UCSF and MCC criteria include MRI findings. 
Possible diagnosis of sCJD is made when there is 
absence of tests; however, it is not a diagnostic 
entity according to the UCSF criteria. Another 
diagnostic criteria set, that of the Centers for 
Disease Control and Prevention (CDC), is based 
on WHO and MCC criteria (8).
Based on the medical history, the clinical manifes-
tations, typical EEG and MRI findings, positive 
14-3-3 and tau proteins, and neuropathological 
examination, the patient presented herein was 
diagnosed with sCJD. The case met the criteria for 
definite diagnosis and did not present any relevant 




Figure 2. Brain magnetic resonance imaging (MRI) studies showing findings consistent with sporadic Creutzfeldt-Jakob disease
a. Axial FLAIR MRI sequence demonstrating hyperintense lesions in the caudate nuclei and putamen bilaterally (arrows) and 
generalized cortical atrophy. b. Coronal T2W MRI sequence revealed atrophy in parietal and temporal cortices as well as subcortical 
atrophy and widening of lateral ventricles (asterisks). c. Single-voxel proton MRI spectroscopy of the right cerebellar hemisphere 
showing reduced NAA:Cr ratios (~0.79) and increased Cho:Cr ratios (~2.44)
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to be the first Colombian case report of sCJD 
using 14-3-3 protein, tau protein and proton MRI 
spectroscopy together as diagnostic tools.
Although sCJD spectrum of clinical manifestations 
is broad, it usually manifests as an irreversible 
course of rapidly progressing dementia with ataxia 
and myoclonus, often leading to death within less 
than one year after disease onset. sCJD has a 
mean illness duration of five months, which is 
consistent with our case report (2,4). Other clinical 
features of sCJD are vague symptoms including 
fatigue, disordered sleep and weight loss, as well as 
neurological manifestations such as ataxia, altered 
sensorium, language deficits, behavior changes, 
visual and auditory hallucinations, parkinsonism, 
seizures and akinetic mutism (2,9). Most of these 
findings were present in our patient.
Abnormal electroencephalographic tracing, when 
present, is suggestive for probable sCJD but is 
not pathognomonic, as some metabolic and toxic 
encephalopathies and other dementias could 
present with abnormal EEG as well. The cerebral 
electrical activity is usually normal or slow in the 
early course of the disease. Later in the course 
of the disease, periodic, biphasic or triphasic 
synchronous sharp-wave complexes may emerge 
and alternate with the background rhythm. These 
typical alterations were found in our patient. The 
sensitivity and specificity of a typical EEG for 
detection of sCJD are 64-67% and 86-91%, 
respectively (10,11).
Sensitivity of brain MRI in probable and definitive 
sCJD cases ranges from 58-71%, and specificity 
ranges from 82-90%; however, MRI may be normal 
Table 1. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease
Diagnostic 
criteria *







2. Visual or cerebellar 
disturbance




1. Typical EEG: Generalized 
triphasic periodic complexes
2. Positive 14-3-3 protein 
assay in CSF in patients 
with a disease duration                            
< 2 years
D. Disease duration < 2 years
E. Routine investigations should 
not suggest an alternative 
diagnosis.
(7)
A. Rapid cognitive decline
B. Symptoms
1. Myoclonus





6. Other focal higher cortical sign (e.g., 
neglect, aphasia, apraxia, acalculia)
C. Tests
1. Positive EEG: Periodic epileptiform 
discharges
2. Positive MRI: Subcortical 
hyperintensity or cortical gyral 
hyperintensity on DWI and 
preferably restricted diffusion on 
ADC map





2. Cerebellar or visual disturbance




1. EEG: Periodic sharp wave 
complexes
2. 14-3-3 protein in CSF in 
patients with a disease duration < 
2 years
3. MR: High signal abnormalities 
in caudate nucleus and putamen 
or at least 2 cortical regions 
(temporal-parietal-occipital) either 
on DWI or FLAIR
C. Disease duration < 2 years
Definite 
sCJD
• Neuropathological confirmation (spongiform encephalopathy in cerebral, cerebellar cortex, or subcortical gray  
   matter) or
• Confirmation of PrPSc by immunocytochemistry or western blot or




≥2 criteria of B and
≥1 criterion of C and
E
A and
≥2 criteria of B and
≥1 criterion of C and
D
≥2 criteria of A and




≥2 criteria of B and
D
N/A
≥ 2 criteria of A and
C
sCJD: sporadic Creutzfeldt-Jakob disease; WHO: World Health Organization; UCSF: University of California San Francisco; MCC: magnetic resonance 
imaging-Creutzfeldt-Jakob Disease Consortium; EEG: electroencephalogram; CSF: cerebrospinal fluid; MRI: magnetic resonance imaging; DWI: 
diffusion-weighted imaging; ADC: apparent diffusion coefficient; FLAIR: fluid-attenuated inversion recovery; PrPSc: disease-causing protease-resistant 
prion protein; N/A: not applicable; CDC: Centers for Disease Control and Prevention
* CDC criteria are based on WHO and MCC criteria (8). Probable sCJD is made when the case meets WHO section A and ≥ 2 criteria of WHO section 
B, and ≥ 1 criteria of MCC section B and WHO section E. CDC diagnostic criteria for definite and possible sCJD are the same as WHO criteria.
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in early stages of the disease. MRI sequences, 
such as DWI and FLAIR, show cerebral atrophy and 
prominent hyperintensities in both basal ganglia 
and cortex, which are common changes in sCJD 
as seen in our case (12). Furthermore, our patient 
had abnormalities on proton MRI spectroscopy, 
which according to the literature, might increase the 
diagnostic accuracy for sCJD. N-acetylaspartate 
to creatine ratios ≤1.21 have been associated to 
sCJD diagnosis with a sensitivity and a negative 
predictive value of 100% (13).
The 14-3-3 protein in the CSF has been reported 
to have a sensitivity between 85% and 96% 
and a specificity between 79% and 96%. As it 
may be present in other conditions such as 
viral encephalitis, metabolic encephalopathy and 
cerebral hemorrhages, the test is not appropriate 
as a general screening test for CJD, but is useful for 
diagnosis of truly suspect cases (14-16). In contrast 
to qualitative 14-3-3 test, ELISA immunoassay for 
the quantitative detection of tau protein in CSF 
has shown superior accuracy with less ambiguous 
results (17). Both the 14-3-3 and tau proteins in 
the CSF of the patient were positive and therefore 
supported the diagnosis of sCJD.
The patient did not receive any treatment before 
death as there are currently no effective therapies 
for prion diseases (4). Unfortunately, it was not 
possible to know the sCJD subtype because the 
immunological analysis of PrPSc and the PRNP 
sequencing were not performed.
The real incidence of prion diseases in Colombia 
is unknown, but it is suspected to be higher than 
believed (18). Our literature search on prion diseases 
revealed that one case of scrapie in 1981 and 29 
human sporadic cases of CJD (18-32) have been 
documented and published in our country. To our 
knowledge, there are no records or evidence of 
vCJD or bovine spongiform encephalopathy in 
Colombia (28,33,34). We found other publications 
such as reviews and correspondences about trans-
missible spongiform encephalopathies (18,33-41). 
General features of the sCJD case reports from 
Colombia are shown in table 2. The majority of these 
sCJD cases occurred in persons between 50 and 
70 years of age, which is a fact consistent with the 
global literature (1,9). sCJD has been reported in 
different regions of the country showing a random 
geographic distribution of the reported cases. 
Overall, there was no significant, personal or familial 
history which had indicated iatrogenic causes or 
suggested differential diagnosis of neurodegenera-
tive diseases. The disease duration in most of the 
cases was reported to be less than eight months.
Transmissible spongiform encephalopathies have 
profound impacts on public health and economy, 
particularly bovine spongiform encephalopathy and 
vCJD because of their potential transmissibility. 
The World Organization for Animal Health (OIE, 
as it was formerly called Office International des 
Epizooties) and the WHO have urged several 
countries to implement policies regarding the 
international trade of animals and their derived 
products, and to state the surveillance, notification, 
data collection, analysis, and confirmation of 
suspected human cases of prion disease as 
mandatory (34,39) (Sierra-Zuleta UE. Avance y 
estado actual de la prevención y vigilancia de 
la encefalopatía espongiforme bovina (EEB) 
en Colombia. Jornada Nacional de Zoonosis y 
Enfermedades Emergentes y Re-emergentes, 
August 21 and 22, 2008. Accessed: June 15, 
2015. Available from: http://sites.google.com/site/
saludpublicaveterinaria).
Colombia was initially considered by the OIE to 
be a country with controlled bovine spongiform 
encephalopathy risk because of the antecedents 
of livestock importation in the 1980s and 
1990s from countries where bovine spongiform 
encephalopathy was documented (28). Since 2001, 
the Instituto Colombiano Agropecuario (ICA) has 
been responsible for the national program for 
prevention of bovine spongiform encephalopathy. 
Moreover, in 2005, the Instituto Nacional de 
Salud gathered efforts with the ICA, the Ministry 
of Social Protection and the Instituto Nacional de 
Vigilancia de Medicamentos y Alimentos (INVIMA) 
to set up a surveillance system for vCJD in the 
framework of the Sistema Nacional de Vigilancia 
en Salud Pública (Sivigila) (34,39) (Sierra-Zuleta 
UE. Avance y estado actual de la prevención 
y vigilancia de la encefalopatía espongiforme 
bovina (EEB) en Colombia. Jornada Nacional 
de Zoonosis y Enfermedades Emergentes y Re-
emergentes, August 21 and 22, 2008. Accessed: 
June 15, 2015. Available from: http://sites.google.
com/site/saludpublicaveterinaria). Thanks to these 
initiatives, Colombia is officially regarded as having 
a negligible bovine spongiform encephalopathy 
risk status since May 2012 (28).
Although Colombia is currently considered to be 
free of bovine spongiform encephalopathy and the 
risk of vCJD cases is consequently low, emergence 
34
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of prion disease forms yet not reported in Colombia 
could occur, with devastating consequences in 
the health and farming industry sectors. Epide-
miological surveillance of prion diseases must 
continue and confirmation procedures of suspected 
cases must be encouraged to keep the risk of 
zoonotic transmission of transmissible spongiform 
encephalopathies to a minimum (28,34,39).
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